Solubility engineering and crystallization of human apolipoprotein D

Protein Science

Volumn 15, Issue 1, 2006, Pages 190-199

  Nasreen, Amber ^a   Vogt, Martin ^a   Hyun, Jin Kim ^a   Eichinger, Andreas ^a   Skerra, Arne ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Characterization; E. coli expression; Gel permeation chromatography; Isolation; Lipocalin; Lipoproteins; Protein engineering; Protein structure folding; Stability and mutagenesis

Indexed keywords

APOLIPOPROTEIN D; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CRYSTALLIZATION; CYTOPLASM; ELUTION; ESCHERICHIA COLI; GEL PERMEATION CHROMATOGRAPHY; HYDROPHOBICITY; MUTAGENESIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEOMICS; SOLUBILITY; X RAY CRYSTALLOGRAPHY;

APOLIPOPROTEINS; APOLIPOPROTEINS D; CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; CLONING, MOLECULAR; CRYSTALLIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; HUMANS; MUTAGENESIS, SITE-DIRECTED; PROTEIN ENGINEERING; SOLUBILITY;

ESCHERICHIA COLI;

EID: 29344467190     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.051775606     Document Type: Article

References (34)

1. Brahms, S. and Brahms, J. 1980. Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism. J. Mol. Biol. 138: 149-178.
2. Collaborative Computational Suite, Number 4 (CCP4). 1994. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50: 760-763.
3. Dale, G.E., Oefner, C., and D'Arcy, A. 2003. The protein as a variable in protein crystallization. J. Struct. Biol. 142: 88-97.
4. Derewenda, Z.S. 2004. The use of recombinant methods and molecular engineering in protein crystallization. Methods 34: 354-363.
5. Fiedler, M. and Skerra, A. 2001. proBA complementation of an auxotrophic E. coli strain improves plasmid stability and expression yield during fermenter production of a recombinant antibody fragment. Gene 274: 111-118.
6. Fiedler, M., Horn, C., Bandtlow, C., Schwab, M.E., and Skerra, A. 2002. An engineered IN-1 F(ab) fragment with improved affinity for the Nogo-A axonal growth inhibitor permits immunochemical detection and shows enhanced neutralizing activity. Protein Eng. 15: 931-941.
7. Fling, S.P. and Gregerson, D.S. 1986. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal. Biochem. 155: 83-88.
8. Geisselsoder, J., Witney, F., and Yuckenberg, P. 1987. Efficient site-directed in vitro mutagenesis. Biotechniques 5: 786-790.
9. Gill, S.C. and von Hippel, P.H. 1989. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182: 319-326.
10. Hall, R.E., Horsfall, D.J., Stahl, J., Vivekanandan, S., Ricciardelli, C., Stapleton, A.M., Scardino, P.T., Neufing, P., and Tilley, W.D. 2004. Apolipoprotein-D: A novel cellular marker for HGPIN and prostate cancer. Prostate 58: 103-108.
11. Huber, R., Schneider, M., Mayr, I., Müller, R., Deutzmann, R., Suter, F., Zuber, H., Falk, H., and Kayser, H. 1987. Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0 Å resolution. J. Mol. Biol. 198: 499-513.
12. Jancarik, J. and Kim, S.H. 1991. Sparse-matrix sampling - A screening method for crystallization of proteins. J. Appl. Crystallogr. 24: 409-411.
13. Jenkins, T.M., Hickman, A.B., Dyda, F., Ghirlando, R., Davies, D.R., and Craigie, R. 1995. Catalytic domain of human immunodeficiency virus type 1 integrase: Identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc. Natl. Acad. Sci. 92: 6057-6061.
14. McElroy, H.E., Sisson, G.W., Schoettlin, W.E., Aust, R.M., and Villafranca, J.E. 1992. Studies on engineering crystallizability by mutation of surface residues of human thymidylate synthase. J. Cryst. Growth 122: 265-272.
15. McPherson, A. 1999. Crystallization of biological macromolecules. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
16. Milne, R.W., Rassart, E., and Marcel, Y.L. 1993. Molecular biology of apolipoprotein D. Curr. Opin. Lipidol. 4: 100-106.
17. Peitsch, M.C. and Boguski, M.S. 1990. Is apolipoprotein D a mammalian bilin-binding protein? New Biol. 2: 197-206.
18. Rassart, E., Bedirian, A., Do Carmo, S., Guinard, O., Sirois, J., Terrisse, L., and Milne, R. 2000. Apolipoprotein D. Biochim. Biophys. Acta 1482: 185-198.
19. Schindler, P.A., Settineri, C.A., Collet, X., Fielding, C.J., and Burlingame, A.L. 1995. Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. Protein Sci. 4: 791-803.
20. Schiweck, W. and Skerra, A. 1995. Fermenter production of an artificial Fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Proteins 23: 561-565.
21. Schlehuber, S., Beste, G., and Skerra, A. 2000. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 297: 1105-1120.
22. Skerra, A. 1994a. A general vector, pASK84, for cloning, bacterial production, and single-step purification of antibody Fab fragments. Gene 141: 79-84.
23. -. 1994b. Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in Escherichia coli. Gene 151: 131-135.
24. -. 2000. Lipocalins as a scaffold. Biochim. Biophys. Acta 1482: 337-350.
25. Skerra, A. and Schmidt, T.G. 2000. Use of the Strep-tag and streptavidin for detection and purification of recombinant proteins. Methods Enzymol. 326: 271-304.
26. Sreerama, N. and Woody, R.W. 2000. Circular dichroism of peptides and proteins. In Circular dichroism - Principles and applications (eds. N. Berova et al.), pp. 601-620. John Wiley & Sons, New York.
27. Strauch, K.L. and Beckwith, J. 1988. An Escherichia coli mutation preventing degradation of abnormal periplasmic proteins. Proc. Natl. Acad. Sci. 85: 1576-1580.
28. Thomas, E.A., Copolov, D.L., and Sutcliffe, J.G. 2003. From pharmacotherapy to pathophysiology: Emerging mechanisms of apolipoprotein D in psychiatric disorders. Curr. Mol. Med. 3: 408-418.
29. Vogt, M. and Skerra, A. 2001. Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. J. Mol. Recognit. 14: 79-86.
30. -. 2004. Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D. Chembiochem 5: 191-199.
31. Yang, C.Y., Gu, Z.W., Blanco-Vaca, F., Gaskell, S.J., Yang, M., Massey, J.B., Gotto Jr., A.M., and Pownall, H.J. 1994. Structure of human apolipoprotein D: Locations of the intermolecular and intramolecular disulfide links. Biochemistry 33: 12451-12455.
32. Yanisch-Perron, C., Vieira, J., and Messing, J. 1985. Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33: 103-119.
33. Zeng, C., Spielman, A.I., Vowels, B.R., Leyden, J.J., Biemann, K., and Preti, G. 1996. A human axillary odorant is carried by apolipoprotein D. Proc. Natl. Acad. Sci. 93: 6626-6630.
34. Zhang, F., Basinski, M.B., Beals, J.M., Briggs, S.L., Churgay, L.M., Clawson, D.K., DiMarchi, R.D., Furman, T.C., Hale, J.E., Hsiung, H.M.,et al. 1997. Crystal structure of the obese protein leptin-E100. Nature 387: 206-209.